Concurrent weekly cisplatin <i>versus</i> triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution

Kinjyo, Yoshino; Nagai, Yutaka; Toita, Takafumi; Kudaka, Wataru; Ariga, Toshio; Shimoji, Yuko; Nakasone, Tadaharu; Taira, Yoichi; Arakaki, Yoshio; Nakamoto, Tomoko; Wakayama, Akihiko; Ooyama, Takuma; Maemoto, Hitoshi; Heianna, Joichi; Aoki, Yoichi

doi:10.1259/bjr.20170241

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 Conversely, outcomes of weekly CDDP regimen for CCRT were found to be better with respect to hematological toxicity in a study conducted by Kinjyo et al in 2017. 12 No definitive conclusions were drawn from these studies. Therefore, 6 randomized trials and 2 retrospective studies were included in our meta-analysis to explore the difference between the different CDDP-alone regimens for patients with LACC.…”

Section: Introductionmentioning

confidence: 90%

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis

Zhu¹,

Ji²,

Qin³

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundRadiotherapy (RT) concurrent with cisplatin (CDDP) is the standard regimen used for treatment of locally advanced cervical carcinoma. In this meta-analysis, we compared the weekly and triweekly single CDDP concomitant chemoradiation regimens for treatment of cervical cancer with respect to compliance, recurrence, survival, and acute adverse effects.Materials and methodsA systematic search for relevant studies was conducted in PubMed, Cochrane Library, EMBASE, and Medline databases. Fixed- or random-effects model was used for pooled analysis. The end points were overall survival, recurrence, compliance, and acute adverse effect reported as odds ratios (ORs) and 95% CIs.ResultsSix randomized trials and two retrospective studies qualified the inclusion criteria. The regimen of triweekly CDDP alone concurrent with RT showed better compliance (OR, 0.49; 95% CI, 0.29–0.83; P=0.009). No significant difference was observed between the 2 arms with respect to recurrence, survival, and acute adverse effects (all P>0.05). However, triweekly CDDP regimen was associated with significantly lower incidence of local recurrence (OR, 1.83; 95% CI: 1.12–3.01; P=0.02), while weekly CDDP regimen was associated with a lower risk of leucopenia (OR, 0.30; 95% CI: 0.10–0.92; P=0.03).ConclusionTriweekly single platinum chemotherapy plus concurrent RT was superior to weekly CDDP regimen with respect to local recurrence and treatment compliance in patients with locally advanced cervical carcinoma.

show abstract

Section: Introductionmentioning

confidence: 90%

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis

Zhu¹,

Ji²,

Qin³

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…Akin retrospective study by Kinjyo et al reported no significant difference in OS, DFS and distant DFS. The 5-year DFS was 88.5% and 87.9% and distant DFS was 83.9% and 84.1% in the triweekly and weekly arm (p = 0.782 and p = 0.938), respectively (18). Kinjyo used a similar protocol as Nagy et al A 2-year complete response of 95.1% and 87.8% in tri-weekly and weekly arms were proclaimed by Panda et al The three-weekly arm used 75 mg/m 2 unlike our study which used 100 mg/m 2 .…”

Section: Discussionmentioning

confidence: 94%

Ten years survival results of randomized study comparing weekly vs. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix

Nanda,

Katke,

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background The current standard of treatment for locally advanced cervical cancer is concurrent chemo-radiation with improved overall survival (OS) by 6% with manageable toxicities. The cisplatin 40 mg/m 2 given weekly is the widely practiced regimen for 4–6 cycles concurrently with irradiation. Materials and methods Two hundred and twelve patients with histologically proven squamous cell carcinoma of cervix with stages IIB to IIIB were enrolled between 2007–2011. External beam radiation dose of 45 Gy in 25 fractions was delivered over 5 weeks. Brachytherapy was delivered by manual afterloading cesium-137 (Cs137) low dose brachytherapy (LDR) using modified Fletcher suit intracavitary applicators to a total dose of 30 Gy to Point A or interstitial template to dose of 21 Gy/3 fractions with remote afterloading iridium-192 (Ir192) high dose brachytherapy (HDR). Patients were randomized to arm A receiving 40 mg/m 2 of concurrent cisplatin weekly and arm B receiving 100 mg/m 2 of concurrent cisplatin triweekly. Results One hundred and nine patients were randomized to weekly cisplatin and one hundred and three patients to triweekly cisplatin at the end of recruitment. At ten years, the OS was higher in the weekly arm (79.8%) compared to triweekly arm (70.9%). Disease free survival (DFS) was almost equal (76.1% and 73.8%) in the weekly and three-weekly arms. There is definite significance in overall DFS with patients receiving the cumulative cisplatin doses of more than 250 mg (p = 0.028). The patients with more than 45 years of age had better overall survival (OS) (79%) with statistical significance 31 (p = 0.020). Conclusion Both cisplatin based triweekly and weekly concurrent chemotherapy are equally effective in terms of OS and DFS.

show abstract

“…122,123 and a retrospective single-institution review. 124 The conclusions from these studies are blurred because of the inclusion of both singleagent cisplatin and mostly combination regimes in a triweekly arm and the inclusion of retrospective studies with adjuvant CTRT in patients postoperatively. 122,123 The safety and efficacy of CTRT(3wkly Pt) over CTRT(wkly Pt) has been demonstrated in 3 randomized trials in LACC.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

Datta

Stutz

Gómez

et al. 2019

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Treatment options in locally advanced cervix cancer (LACC) have evolved around radiation therapy (RT) and/or chemotherapy (CT), hypoxic cell sensitizers, immunomodulators (Imm), and locoregional moderate hyperthermia (HT). A systematic review and network meta-analysis was conducted to synthesize the evidence for efficacy and safety in terms of long-term locoregional control (LRC), overall survival (OS), and grade !3 acute morbidity (AM) and late morbidity (LM). Five databases were searched, and 6285 articles (1974-2018) were screened per the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. Fifty-nine randomized trials in untreated LACC without surgical intervention were shortlisted. These used 13 different interventions: RT alone and/or neoadjuvant CT (NACT), adjuvant CT (ACT), concurrent chemoradiation therapy (CTRT) (weekly cisplatin [CDDP]/3-weekly CDDP/combination CT with CDDP/non-CDDP-based CT), hypoxic cell sensitizers, Imm, or HT. Odds ratios (ORs) using random effects network meta-analysis were estimated. Interventions for each endpoint were ranked according to their corresponding surface under cumulative ranking curve values. Of the 9894 patients evaluated, the total events reported for LRC, OS, AM, and LM were 5431 of 8197, 4482 of 7958, 1710 of 7183, and 441 of 6333, respectively. ORs and 95% credible intervals (CrIs) for the 2 best strategies were HT þ RT versus CTRT þ ACT (OR, 1.23; 95% CrI, 0.49-3.19) for LRC, CTRT (3-weekly CDDP) versus HTCTRT (OR, 1.14; 95% CrI, 0.35-3.65) for OS, RT þ ACT versus RT (OR, 0.01; 95% CrI, 0.00-1.04) for AM, and NACT þ RT þ ACT versus RT þ Imm (OR, 0.42; 95% CrI, 0.02-7.39) for LM. The 3 interventions with the highest cumulative surface under cumulative ranking curve values for all 4 endpoints were HTRT, HTCTRT, and CTRT (3-weekly CDDP). Articles with low risk of bias and those published during 2004 to 2018 also retained these interventions as the best. Two-step cluster analysis grouped these 3 modalities in a single distinctive NotedAn online CME test for this article can be taken at https:// academy.astro.org.

show abstract

Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution

Cited by 7 publications

References 21 publications

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis

Ten years survival results of randomized study comparing weekly vs. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix

Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About